Format

Send to

Choose Destination
Naunyn Schmiedebergs Arch Pharmacol. 2009 Apr;379(4):413-5. doi: 10.1007/s00210-008-0384-6. Epub 2008 Dec 19.

Should we be cautious on the use of commercially available antibodies to dopamine receptors?

Author information

1
Section of Pharmacology, Department of Biomedical Sciences and Biotechnologies, University of Brescia Medical School, V.le Europa 11, 25124, Brescia, Italy.

Abstract

Evidence indicate that it is difficult to obtain specific antibodies to G protein-coupled receptors and different technical difficulties may allow the generation of antibodies that lack specificity. We conducted experiments to validate the specificity of commercially available antibodies raised against dopamine (DA) receptors hD(1), hD(4), and hD(5) using a transfection approach: we studied whether, in HEK 293 cells selectively transfected with the various cloned subtypes, each antibody generates bands only in cells expressing its cognate receptor but not in those expressing the other DA receptors. Our results demonstrated that hD(1) and hD(4) receptor antibodies recognize not only their respective epitope, but also other DA receptor subtypes, while for the hD(5) receptor detection, we observed a signal only in the lane loaded with hD(5)-transfected HEK 293 cells, although with a lack of purity. Therefore, we recommend caution on the use of commercially available DA receptor antibodies.

PMID:
19096766
DOI:
10.1007/s00210-008-0384-6
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center